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1. Introduction 
2-glycoprotein I is a lipid-binding 50-kDa glycoprotein that circulates in plasma at a 
concentration of approximately 4 µM (200 µg/ml). The amino acid sequence of human 2-
glycoprotein I was completely determined (1), the cDNAs have been isolated (2, 3) and the 
crystal structure has been solved (4). 2-glycoprotein I is a member of the so-called 
"complement control protein" (CCP) superfamily, whose members are identified by the 
presence of one or more of a motif containing a characteristic disulfide bond pattern (5). 
These motifs are called CCP or sushi domains. CCP repeats are units of approximately 60 
amino acids with a relatively invariant arrangement of 2 disulfide bonds and a number of 
other highly conserved residues. Other members of the CCP superfamily include at least 12 
complement proteins, the B subunit of blood clotting factor XIII, haptoglobin, the interleukin 
2 receptor and selectins. 2-glycoprotein I is made up entirely of five CCP repeats. CCP5 
diverges from the norm for CCPs, including CCPs 1-4 in that it has a relatively unique 
pattern of 3 disulfide bridges (6), and contains a positively-charged sequence, CKNKEKKC 
(residues 281-288), that mediates its binding site for anionic phospholipid (7). The crystal 
structure of 2-glycoprotein I showed the four CCP domains 1-4 are arranged like a beads 
on a sting and CCP5 folds back giving fishhook-like conformation. The CCP5 contains a 
central spiral structure with positively charged motif CKNKEKKC close to a hydrophobic 
patch (LAFW). Β2-glycoprotein I anchors to the anionic phospholipid membrane surface via 
CCP5 with its hydrophobic loop adjacent to the positively charged lysine rich region in 
CCP5. Subsequently, β2-glycoprotein I penetrates the membrane interfacial headgroup 
region. This binding restricts the mobility of the lipid side chains and aggregates the vesicles 
without inducing fusion (8-10). In addition to anionic phospholipids, β2-glycoprotein I 
binds to sulfatide (11), heparin (12), complement C3 (13), annexin A2 (14), platelet 
glycoprotein Ib (15), megalin (16), apolipoprotein receptor 2' (17) von Willebrand factor (18, 
19) and possibly many others ligands. The solution structure of 2-glycoprotein I was 
studied by small angle X-ray scattering (20), the experimentally derived curves fitted poorly 
to the simulated scattering curves calculated from the crystallographic coordinates of 
human b2GPI, suggesting different conformation in solution. Recent studies with negative 
staining electron microscopic studies showed 2-glycoprotein I can exist in two different 
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conformations – a circular conformation due to the interaction of CCP1 with CCP5 and an 
open elongated conformation consistent with the fishhook-like structure seen in the 
crystallographic studies (21). In closed conformation β2-glycoprotein I bind less well to 
anionic phospholipids or to complement C3 (13). Binding to anionic phospholipids, and 
possibly other ligands stabilizes the elongated conformation (22). Circulating plasma β2-
glycoprotein I contains free thiols and these moieties are proposed to interaction with 
platelets and endothelium, protecting these cells from oxidative stress (18). Oxidized form 
β2-glycoprotein I is increased in patients with thrombosis (23). Oxidized β2-glycoprotein I 
induces human dentritic cell maturation and promotes a T helper type I response (24). These 
studies imply the antibody response to 2-glycoprotein I are due post translational 
modifications due to oxidative stress.  
2-glycoprotein I was designated as apolipoprotein H initially as it could be isolated from 
very low density lipoprotein fractions and had high affinity for triglyceride-rich particles 
(25). However, recent studies do not suggest an interaction between 2-glycoprotein I with 
either high or low density lipoproteins (26).  
Despite the extensive physicochemical characterization, the physiological role of 2-
glycoprotein I remains uncertain. Based on several in vitro studies, a wide range of functions 
have been attributed such as regulation of coagulation (27), modulation of complement 
activity and clearance of apoptotic cells from the circulation (28). In this review, we will 
summarize newer data on the possible physiological role of 2-glycoprotein I.  
2. Modulation of hemostasis 
Since 2-glycoprotein I is the target of the majority of antiphospholipid antibodies 
associated with thrombosis, an anticoagulant function for 2-glycoprotein I was anticipated. 
Anionic phospholipid surfaces play an essential role in normal hemostasis by providing a 
site for the assembly of enzyme-cofactor complexes involved in virtually every step of the 
enzymatic cascade that results in the generation of fibrin, which polymerizes to form an 
insoluble fibrin clot. In normal cells, anionic phospholipids such as phosphatidylserine are 
present only in the inner leaflet of the membrane bilayer. Platelets externalize anionic 
phospholipid when stimulated by agonists. Binding of β2-glycoprotein I to anionic 
phospholipid vesicles (29) and platelets (30, 31) is accompanied by inhibition of 
phospholipid-dependent coagulation tests (27, 32), suggesting a likely physiological role of 
β2-glycoprotein I in the regulation of coagulation, particularly on activated platelets and 
possibly on other cell surfaces. In addition, β2-glycoprotein I inhibits the contact activation 
of the intrinsic coagulation pathway (15, 33). 2-glycoprotein I binds to factor XI with an 
affinity equivalent to that of high molecular weight kininogen. The binding inhibits the 
activation to factor XI by thrombin and FXIIa. This was suggested to be a mechanism, by 
which 2-glycoprotein I may modulate thrombin generation. 2-glycoprotein I also binds to 
heparin – a fact used in its isolation (12, 29). Heparin binding site had been localized to the 
positively charged CCP5 (12). Heparin also promotes plasmin cleavage of 2-glycoprotein I 
at Lys317-Thr318 bond (34). Plasmin-cleaved 2-glycoprotein I has markedly decreased 
affinity for anionic phospholipid. This form of cleaved 2-glycoprotein I is seen in patients 
treated with streptokinase and in patients with disseminated intravascular coagulation (35), 
showing this cleavage reaction can occur in vivo during accelerated fibrinolysis.  
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Several procoagulant effect of β2-glycoprotein I have also been described. β2-glycoprotein I 
binds to thrombin and protects it from inactivation by heparin cofactor II/heparin complex 
(36). Furthermore, Mori et al (37) showed β2-glycoprotein inhibited activated protein C 
inactivation of factor Va – an effect diminished by the addition of phospholipids. At similar 
concentration, β2-glycoprotein I inhibited weakly factor Va- and phospholipid-dependent 
prothrombinase activity. The depletion of beta β2-glycoprotein I from plasma led to only a 
slight shortening of the diluted Russell's viper venom-dependent clotting time, but to a 
strong and significant potentiation of the anticoagulant activity of APC. These results 
suggest that under certain physiological conditions β2-glycoprotein I may have 
procoagulant function.  
In contrast to these hemostatic activities demonstrated in vivo, neither the β2-glycoprotein I-
deficient mice (generated by homologous recombination) nor β2-glycoprotein I-deficient 
individuals exhibit any bleeding manifestations (38-40). On the contrary, β2-glycoprotein I-
deficient mice have diminished rate of thrombin generation compared with normal or even 
with heterozygous mice. No significant differences in clotting time were observed in plasma 
from these three genotypes when measured by dRVVT, dKCT, aPTT, and protein C 
pathway assays (41). Hereditary deficiency of β2-glycoprotein I was reported since 1968 
(42), and its potential association with risk of thrombosis had been examined. Bansci et al. 
(43) have described two brothers with total deficiency of β2-glycoprotein I, one of whom 
had experienced recurrent unexplained thrombosis by age 36. However, six other 
heterozygous individuals (ages 9-73) from this family and the proband’s brother with 
homozygous deficiency were free of thrombosis. Takeuchi et al (39) described two 
asymptomatic individuals with complete deficiency of β2-glycoprotein I. The routine 
coagulation assays were normal. A slight shortening of the DRVVT was observed in these 
individuals, which interestingly were not corrected by exogenous addition of 2-
glycoprotein I.  
Thrombosis is a complex multigene phenotype (44). Because of the large number of genes 
that influence this phenotype teasing out the role of 2-glycoprotein I in in this 
prothrombotic phenotype will be difficult. It is also possible that the thrombosis seen with 
antiphospholipid antibodies is not related to any of interaction identified above.  
3. 2-glycoprotein I as an opsonin 
The term opsonins is used to refer molecules that target a cell for phagocytosis. A number of 
observations suggest 2-glycoprotein I can be an opsonin for clearance of anionic 
phospholipid vesicles containing surfaces from the circulation. In normal cells, anionic 
phospholipids such as phosphatidylserine are present only in the inner leaflet of membrane 
bilayer. There is transbilayer movement of phosphatidylserine during apoptosis and 
phosphatidylserine exposed can be a tag for their clearance by macrophages (45-47). In 
artificial membranes, the phosphatidylserine content has to be at least 5-10% before a 
significant binding of β2-glycoprotein I could be observed (48). Nevertheless, the binding of 
β2-glycoprotein I to phosphatidylserine containing surfaces such as apoptotic cells and 
platelet microvesicles have been shown (49, 50). In addition to the anionic phospholipids, 
2-glycoprotein I is also shown to bind the Ro/SSA, a 60 kDa a nuclear antigen and target of  
autoantibodies in primary Sjogren syndrome (19). Ro/SSA translocates to cell surface 
during apoptosis and can serve as additional binding site. The complex of anionic 
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phospholipid and ß2-glycoprotein I are taken into a receptor-mediated pathway by 
macrophages and possibly endothelial cells also. The phagocytic receptors mediating the 
uptake have been shown to be toll-like receptor 4 in macrophages (51) and lipoprotein 
receptor related family members (49). In endothelial cells toll-like receptor 2 and 4 (52, 53), 
annexin A2 (14), and apolipoprotein E receptor 2 (54) have been implicated. Deficiencies of 
factors, implicated in the removal of apoptotic cells such as lactadherin and Gas6 receptors, 
are associated with systemic lupus erythematosus and autoimmunity (55). However, no 
immunological dysfunction is reported in β2-glycoprotein I deficiency. 
2-glycoprotein I may also have a role in the clearance of exogenous liposomes. Liposomes 
have been used extensively as vehicles for drug delivery and following in vivo infusions, 
liposomes are preferentially taken up by the mononuclear phagocytic cells of the 
reticuloendothelial system (56). In 1982, Wurm et al (57) showed that infusion of ß2-
glycoprotein I in rats results in an accelerated clearance of triglyceride-rich vesicles from the 
circulation. The clearance of liposomes by the phagocytic cells, is markedly affected lipid 
composition of the liposomes and anionic phospholipid containing are cleared very rapidly 
from blood (56). By analyzing the proteins that associate with the liposomes in blood, Chonn 
et al. have identified 2-glycoprotein I as a major protein associated with rapidly cleared 
liposomes  and noted that pretreating the mice with anti-2-glycoprotein I antibodies  
markedly increased the circulating half-life of the liposomes (58). It is interesting to note that 
in 1982, Wurm et al (57) showed that infusion of ß2-glycoprotein I in rats results in an 
accelerated clearance of triglyceride-rich vesicles from the circulation.  
The complement system is involved in the clearance of dead cells and debris from the 
circulation and recently a role for β2-glycoprotein I its regulation has been identified (13). 
The elongated and open conformation of β2-glycoprotein I binds to C3 and induces a 
conformational changes so that the regulator factor H binds. As factor H promotes factor I-
induced the cleavage of C3, 2-glycoprotein I acts as special cofactor for factor H and factor 
I. The enhanced the degradation of C3 limits further complement amplification. Deficiencies 
of complement factor H and I are associated atypical hemolytic uremic syndrome and no 
such association has been described for 2-glycoprotein I.  
4. A role in gestation 
Because of the association with fetal loss and anti-2-glycoprotein I antibodies, a role in 
gestation has been proposed. Infusion of cyanine labeled 2-glycoprotein I in mice show 
preferential localization on the endothelium of uterine vessels and at the implantation sites 
in pregnant mice (59), suggesting a role in early gestation. However, the 2-glycoprotein I 
null mice were fertile and carried viable fetuses to term and there were no thrombosis in 
placental vessels (60). Nevertheless, there was an 18% reduction in the number of viable 
implantation sites and reduced fetal weight and fetal:placental weight ratio in late gestation 
in 2-glycoprotein I null mice.  
5. 2-glycoprotein I and angiogenesis 
2-glycoprotein I is enzymatically cleaved by plasmin at the peptide bond between Lys317-
Thr318 to form a cleaved form 2-glycoprotein I (61, 62). This form is seen in the circulation 
in patients with increased fibrinolysis. The cleaved form of 2-glycoprotein I binds to 
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plasminogen and inhibits plasmin generation. In addition to modulating fibrinolysis, a role 
in angiogenesis had been proposed for the cleaved form of 2-glycoprotein I. The cleaved 
form of 2-glycoprotein I inhibits endothelial cell proliferation in vitro, inhibits 
neovascularization into subcutaneously implanted angiogenic matrices and the growth of 
orthotopic prostate cancer in C57BL/6 mice (63, 64). The cleaved 2-glycoprotein I strongly 
reduced HUVEC growth and proliferation as evidenced by the MTT and BrdU assay and 
delayed cell cycle progression arresting endothelial cells  in the S-and G2/M-phase (65). 
However, the cleaved form of 2-glycoprotein I can also be promote angiogenes is as it 
binds angiostatin 4.5 (plasminogen kringle 1-5) and attenuates its antiangiogenic property 
(66). The murine  in vivo apparently displayed only mild anti-angiogenic properties. 2-
glycoprotein I deficient mice developed larger tumors with more vessels than 2-
glycoprotein I replete mice but no survival benefit is conferred to tumor bearing animals 
regardless of β2GPI status raising questions about the its pathophysiological role in 
tumorigenesis(66).  
6. Conclusion 
Since its discovery in the sixties and following the recognition that it is the antigenic target 
for antiphospholipid antibodies in nineties, several structural and functional studies have 
been described. However, there is no convincing pathogenetic mechanism or theoretical 
framework for the hypercoagulable state associated with antibodies to this protein. Many 
hypotheses have been proposed based on in vitro findings and most of them revolve on the 
anionic phospholipid binding properties of 2-glycoprotein I. At least two patients are 
described with antiphospholipid syndrome who had mutations in 2-glycoprotein I 
rendering it in capable of binding phospholipids (67, 68), questioning its phospholipid 
binding in pathogenesis. These findings underscore the importance finding its physiological 
function to elucidate the mechanism of thrombosis seen with antibody to this molecule.  
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